コンテンツへスキップ
Merck

Personalized Mapping of Drug Metabolism by the Human Gut Microbiome.

Cell (2020-06-12)
Bahar Javdan, Jaime G Lopez, Pranatchareeya Chankhamjon, Ying-Chiang J Lee, Raphaella Hull, Qihao Wu, Xiaojuan Wang, Seema Chatterjee, Mohamed S Donia
要旨

The human gut microbiome harbors hundreds of bacterial species with diverse biochemical capabilities. Dozens of drugs have been shown to be metabolized by single isolates from the gut microbiome, but the extent of this phenomenon is rarely explored in the context of microbial communities. Here, we develop a quantitative experimental framework for mapping the ability of the human gut microbiome to metabolize small molecule drugs: Microbiome-Derived Metabolism (MDM)-Screen. Included are a batch culturing system for sustained growth of subject-specific gut microbial communities, an ex vivo drug metabolism screen, and targeted and untargeted functional metagenomic screens to identify microbiome-encoded genes responsible for specific metabolic events. Our framework identifies novel drug-microbiome interactions that vary between individuals and demonstrates how the gut microbiome might be used in drug development and personalized medicine.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ヒドロコルチゾン, ≥98% (HPLC)
Supelco
アスパルテーム, analytical standard
Sigma-Aldrich
クロファジミン
Sigma-Aldrich
ミコフェノール酸, ≥98%
Sigma-Aldrich
アロプリノール, xanthine oxidase inhibitor
Sigma-Aldrich
ケトコナゾール, 99.0-101.0% (EP, titration)
Sigma-Aldrich
ニカルジピン 塩酸塩, powder, ≥98%
Sigma-Aldrich
クロナゼパム, powder
Sigma-Aldrich
ミソプロストール, ≥99% (HPLC)
Sigma-Aldrich
Mycophenolate mofetil, ≥98% (HPLC)
Supelco
スルファメトキサゾール
Supelco
メトロニダゾール, analytical standard
Sigma-Aldrich
5-フルオロ-5′-デオキシウリジン
Sigma-Aldrich
ミソプロストール遊離酸, ≥90%
Supelco
リスペリドン, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
ジドブジン, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
ビサコジル, analytical standard, for drug analysis
Supelco
カペシタビン, Pharmaceutical Secondary Standard; Certified Reference Material